核酸治療的全球市場、研發與應用

本報告已在2011年07月19日停止出版。

簡介

以核酸來治療並非是一種新概念，這是一種利用其與人類基因構造之相似性的療法。

專研製藥、生技、醫療儀器等生命科學領域的美國市調公司 Kalorama Information （總公司：紐約州），調查分析了核酸治療的全球市場後，出版了一本綜合報告書 "Nucleic Acid-Based Therapeutics: World Markets, Developments, and Applications" 。

報告書內容包括：六大核酸治療技術的疾病預防與治療應用，以及對市場未來的影響分析，全書共599頁，內容綱要摘記如下：

第1章 摘要

• 背景
• 調查範圍與方法論
• 市場規模與成長
• 產業結構
• 主要策略性趨勢

第2章 治療用核酸技術

• Antisense
• Antisense的途徑
  • 飲食
  • 微注入
  • 微脂囊膠囊（Liposome Capsule）
• Oligonucleotides 的種類
  • 舊有的 Antisense
  • Ribozymes Antisense
  • 三鏈 Antisense
• RNA干涉 (RNAi)
• 基因療法
• Nucleoside Analogs
• Ribozymes
• 適合體
• 三鏈 Antisense

第3章 核酸治療應用

• 癌症
• 類風濕性關節炎
• 糖尿病
• 心臟血管疾病
  • 高血壓
  • 冠狀動脈疾病 (CAD)
  • 充血性心臟衰竭 (CHF)
• 自我免疫疾病
• 神經系統疾病
  • 末稍神經 / 骨骼肌疾病與障礙
  • 中樞神經疾病與障礙
• 病毒感染
• 其他

第4章 核酸治療市場

• 背景
• 各適應症市場
  • 癌症
  • 類風濕性關節炎
  • 糖尿病
  • 心臟血管疾病
  • 自我免疫疾病
  • 神經系統疾病
  • 病毒感染
  • 其他
• 各地區市場：全球七大市場
  • 美國
  • 日本
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第5章 企業資訊

第6章 結論與策略性影響

目錄

The concept of nucleic acid-based therapeutics is not a new one. For a long time it has been thought that molecules similar to those that make up our genetic structure would make effective therapeutics. It is an idea whose time has come.

There are six types of nucleic acid-based therapeutics that have been proposed. Some have made it to market, others are still in development, and some have been put on the back burner due to technical difficulties. The six technologies examines in this study are:

• Antisense
• Ribonucleic acid inhibition (RNAi)
• Gene therapy
• Nucleoside analogs
• Ribozymes, and
• Aptamers

This report focuses on the application of nucleic acid-based therapeutics to the prevention and treatment of various diseases and disorders:

• Cancer
• Rheumatoid arthritis
• Diabetes (Types I and II)
• Cardiovascular disease (hypertesion, Coronary artery disease, and congestive heart failure)
• Autoimmune diseases (psoriasis, lupus erythematosus, psoriatic arthritis, and scleroderma)
• Neurological Diseases (peripheral neuropathies, Alzheimers disease, epilepsy, Parkinsons disease, multiple sclerosis, severe traumatic brain injury, and spinal cord injury)
• Viral Diseases, and
• Miscellaneous conditions

The report examines the options that these new therapeutics present, the progress that is being made in these fields, and the motivations for broader pharmaceutical industry involvement in these markets. The major market effects of nucleic acid-based therapeutics are seen as having the potential to significantly impact the seven major world healthcare markets over the next ten years. The trends selected in conjunction with the growing interest in preventive medicine alone, and gene vaccines specifically, and the application to current health priorities present the most informative picture of advances in this field and the markets that result.

Market analysis for this report considers the various applications of nucleic acid-based therapeutics rather than the markets for specific products in the seven major world healthcare markets:

• United States
• Japan
• Germany
• France
• United Kingdom
• Italy, and
• Spain

The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as in-depth interviews and discussions with experts in the field, including medicinal chemists, experts in genetics and genomics, medical professionals, research scientists, business development managers, and marketing managers.

Chapter One: Executive Summary

• Background
• Scope and Methodology
• Market Size and Growth
• Industry Structure
• Key Strategic Trends

Chapter Two: Therapeutic Nucleic Acid Technologies

• Ribonucleic Acid Inhibition (RNAi)
• Gene Therapy
• Nucleoside Analogs
• Ribozymes
• Aptamers
• Triplex Antisense

Chapter Three: Applications of Nucleic Acid-Based Therapeutics

• Cancer
• Rheumatoid Arthritis
• Diabetes
• Cardiovascular Diseases
• Hypertension
• Coronary Artery Disease (CAD)
• Congestive Heart Failure (CHF)
• Autoimmune Diseases
• Neurological Diseases
• Peripheral Nerve and Skeletal Muscle Diseases and Disorders
• Central Nervous System Diseases and Disorders
• Viral Infections
• Miscellaneous Applications

Chapter Four: The Markets for Nucleic Acid-Based Therapeutics

• Background
• Disease Applications
• Cancer
• Rheumatoid Arthritis
• Diabetes
• Cardiovascular Disease
• Autoimmune Diseases
• Neurological Diseases
• Viral Diseases
• Miscellaneous Conditions
• The Seven Major World Markets
• United States
• Japan
• Germany
• France
• United Kingdom
• Italy
• Spain
• Chapter Five: Company Profiles
• Alnylam Pharmaceuticals
• Amaxa Biosystems GmbH
• Antisense Therapeutics Ltd.
• Ark Therapeutics Group Plc.
• Atugen
• BioVex Ltd.
• Cell Genesys
• Cenix BioScience, GmbH
• Ceregene Inc.
• Collateral Therapeutics, Inc. (Division of Schering AG)
• Copernicus Therapeutics, Inc.
• Crucell NV
• Dharmacon, Inc. (Subsidiary of Fisher Scientific)
• ExpressOn Biosystems Ltd.
• Galapagos Genomics
• Genta Inc.
• Genteric, Inc.
• GenVec, Inc.
• Gilead Sciences
• Hybridon
• Introgen Therapeutics, Inc.
• Isis Pharmaceuticals, Inc.
• Mirus Bio Corporation
• Oxford BioMedica
• Selective Genetics
• Sirna Therapeutics
• Targeted Genetics
• Transgene
• Valentis
• Vectron Therapeutics AG
• Chapter Six: Conclusions and Strategic Implications

Appendix A: Glossary

Appendix B: Company Names and Addresses

• List of Tables
  • Table 1-1: Market Potential for Nucleic Acid-Based Therapeutics in the Global Healthcare Markets by Application: 2004 - 2014
  • Table 1-2: Market Potential for Nucleic Acid-Based Therapeutics in the Seven Major World Healthcare Markets by Application: 2004 - 2014
  • Table 3-1: Estimated Incidence of Cancer in the Major World Healthcare Markets (Millions of Cases)
  • Table 3-2: Age Distribution for the Populations of the Seven Major World Healthcare Markets: 2004
  • Table 3-3 : Therapeutic Options in the Treatment of Cancer
  • Table 3-4: Key Nucleic Acid-Based Cancer Therapeutics in Development
  • Table 3-5: Prevalence of Rheumatoid Arthritis Cases in the United States for the Total Population and Those 45 Years of Age and Older: 2004 - 2014
  • Table 3-6: Prevalence of Rheumatoid Arthritis in the Major World Healthcare Markets (Millions of Cases)
  • Table 3-7: Key Nucleic Acid-Based Rheumatoid Arthritis Therapeutics in Development
  • Table 3-8: Characteristics of Type 1 and Type 2 Diabetes Mellitus
  • Table 3-9: Key Nucleic Acid-Based Diabetes Therapeutics in Development
  • Table 3-10: Prevalence of Diagnosed Diabetes (Type I vs Type II) in the Major World Healthcare Markets 2004-2014
  • Table 3-11: Prevalence of Cardiovascular Diseases by Type (Hypertension, CAD, CHF) in the Major World Healthcare Markets 2004-2014
  • Table 3-12: Therapeutic Strategies for Symptomatic Congestive Heart Failure
  • Table 3-13: Pharmacological Response to the Pathophysiology of Cardiac Performance
  • Table 3-14: Key Nucleic Acid-Based Cardiovascular Therapeutics in Development
  • Table 3-15: Recognized Autoimmune Diseases
  • Table 3-16: Prevalence of Autoimmune Diseases by Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) in the Major World Healthcare Markets 2004-2014
  • Table 3-17: Neurological Diseases and Disorders as Classified by the United States National Institute of Neurological Disorders and Stroke (NINDS): 2002
  • Table 3-18: Classification of Diseases and Disorders of Peripheral Nerve and Skeletal Muscle
  • Table 3-19: Classification of Diseases and Disorders of the Central Nervous System
  • Table 3-20: Prevalence of Neurological Diseases by Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) in the Major World Healthcare Markets 2004-2014
  • Table 3-21: Key Nucleic Acid-Based Neurological Therapeutics in Development
  • Table 3-22: Key Nucleic Acid-Based Viral Therapeutics and Vaccines in Development
  • Table 3-23: Prevalence of Key Viral Diseases by Type (CMV, HSV, HPV, HCV, HIV, HBV, WNV) in the Major World Healthcare Markets 2004-2014
  • Table 3-24: Key Nucleic Acid-Based Therapeutics and Vaccines in Development for Miscellaneous Applications
  • Table 4-1: Populations of the Seven Major World Healthcare Markets 2004-2014
  • Table 4-2: Cancer Markets in the Seven Major World Healthcare Markets by Country: 2004-2014
  • Table 4-3: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Cancer in the Seven Major World Healthcare Markets by Country 2004 - 2014
  • Table 4-4: Rheumatoid Arthritis Markets in the Seven Major World Healthcare Markets by Country 2004 - 2014
  • Table 4-5: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Rheumatoid Arthritis in the Seven Major World Healthcare Markets by Country: 2004 - 2014
  • Table 4-6: Diabetes Markets in the Seven Major World Healthcare Markets by Country and Type (Insulin vs Oral Hypoglycemics) 2004 - 2014
  • Table 4-7: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Diabetes in the Seven Major World Healthcare Markets by Country 2004 - 2014
  • Table 4-8: Cardiovascular Disease Markets in the Seven Major World Healthcare Markets by Countryand Type (Hypertension, CAD, CHF) 2004 - 2014
  • Table 4-9: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Cardiovascular Disease in the Seven Major World Healthcare Markets by Country and Type (Hypertension, CAD, CHF) 2004 - 2014
  • Table 4-10: Autoimmune Disease Markets in the Seven Major World Healthcare Markets by Country and Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) 2004 - 2014
  • Table 4-11: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Autoimmune Diseases in the Seven Major World Healthcare Markets by Country and Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) 2004 - 2014
  • Table 4-12: Neurological Disease Markets in the Seven Major World Healthcare Markets by Country and Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) 2004 - 2014
  • Table 4-13: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Neurological Diseases in the Seven Major World Healthcare Markets by Country and Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) 2004 - 2014
  • Table 4-14: Market Potential for Nucleic Acid-Based Therapeutics in the Global Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-15: Market Potential for Nucleic Acid-Based Therapeutics in the Seven Major World Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-16: Market Potential for Nucleic Acid-Based Therapeutics in the United States Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-17: Market Potential for Nucleic Acid-Based Therapeutics in the Japanese Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-18: Market Potential for Nucleic Acid-Based Therapeutics in the German Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-19: Market Potential for Nucleic Acid-Based Therapeutics in the French Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-20: Market Potential for Nucleic Acid-Based Therapeutics in the United Kingdoms Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-21: Market Potential for Nucleic Acid-Based Therapeutics in the Italian Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
  • Table 4-22: Market Potential for Nucleic Acid-Based Therapeutics in the Spanish Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
• List of Figures
  • Figure 1-1: Composition by Disease Area of the Market Potential for Nucleic Acid Therapeutics in the Global Healthcare Markets: 2004
  • Figure 2-1: The General Shape of Short Hairpin RNAs (shRNAs)
  • Figure 2-2: The Purine Bases of Nucleic Acid Structure
  • Figure 2-3: The Pyrimidine Bases of Nucleic Acid Structure
  • Figure 2-4: 23-Dideoxynucleoside Analogs
  • Figure 2-5: Structures of Allopurinol and Hypoxanthine
  • Figure 2-6: Structures of Methotrexate and Trimethoprim
  • Figure 2-7: Structure of 5-Iododeoxyuridine
  • Figure 2-8: Structure of Acyclovir
  • Figure 2-9: Structure of Ganciclovir
  • Figure 2-10: Structure of Arabinosyladenine
  • Figure 2-11: Structure of Arabinosylcytosine
  • Figure 2-12: Structure of 3-Azido-23-Dideoxythymidine (AZT)
  • Figure 2-13: Structure of 2,3-Dideoxycytidine (ddC)
  • Figure 2-14: Structure of 2,3-Dideoxyinosine (ddI)
  • Figure 2-15: Structure of Metallotexaphyrin
  • Figure 3-1: Distribution of Cancer Incidence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-2: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group: 2003 - 2013
  • Figure 3-3: Distribution of Rheumatoid Arthritis Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-4: Distribution of Type I Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-5: Distribution of Type II Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-6: Distribution of All Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-7: Distribution of Hypertension Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-8: Distribution of Coronary Artery Disease (CAD) Prevalence by Major Healthcare Market: 2004, 2009, 2014:
  • Figure 3-9: Distribution of Congestive Heart Failure (CHF) Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-10: Distribution of All Cardiovascular Disease (CVD) Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-11: Distribution of Psoriasis Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-12: Distribution of Lupus Erythematosus Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-13: Distribution of Psoriatic Arthritis Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-14: Distribution of All Scleroderma Prevalence by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-15: Distribution of All Selected Autoimmune Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-16: Structure of the Normal Motor Neuron
  • Figure 3-17: Distribution of Peripheral Neuropathy Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-18: Distribution of Alzheimers Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-19: Distribution of Epilepsy Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-20: Distribution of Parkinsons Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-21: Distribution of Multiple Sclerosis Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-22: Distribution of Severe Brain Injury Incidences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-23: Distribution of Spinal Cord Injury Incidences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-24: Distribution of All Selected Neurological Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-25: Distribution of Cytomegalovirus (CMV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-26: Distribution of Herpes Simplex Virus (HSV-1/HSV-2) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-27: Distribution of Human Papilloma Virus (HPV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-28: Distribution of Hepatitis C Virus (HCV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-29: Distribution of Human Immunodeficiency Virus (HIV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-30: Distribution of Hepatitis B Virus (HBV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-31: Distribution of West Nile Virus (WNV) Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 3-32: Distribution of All Selected Viral Infections by Major Healthcare Market: 2004, 2009, 2014
  • Figure 4-1: Distribution of the Replacement Market Potential for Nucleic Acid-Based Cancer Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-2: Percentage Composition of the Market Potential For Nucleic Acid-Based Cancer Therapeutics Among The Seven Major World Healthcare Markets
  • Figure 4-3: Distribution of the Replacement Market Potential for Nucleic Acid-Based Rheumatoid Arthritis Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-4: Percentage Composition of the Market Potential For Nucleic Acid-Based Rheumatoid Arthritis Therapeutics Among The Seven Major World Healthcare Markets
  • Figure 4-5: Distribution of the Replacement Market Potential for Nucleic Acid-Based Diabetes Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-6: Percentage Composition of the Market Potential for Nucleic Acid-Based Diabetes Therapeutics Among the Seven Major World Healthcare Markets
  • Figure 4-7: Distribution of the Replacement Market Potential for Nucleic Acid-Based Cardiovascular Disease Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-8: Percentage Composition of The Market Potential For Nucleic Acid-Based Cardiovascular Disease Therapeutics Among the Seven Major World Healthcare Markets
  • Figure 4-9: Distribution of the Replacement Market Potential for Nucleic Acid-Based Autoimmune Disease Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-10: Percentage Composition of The Market Potential For Nucleic Acid-Based Cardiovascular Disease Therapeutics Among The Seven Major World Healthcare Markets
  • Figure 4-11: Distribution of the Replacement Market Potential for Nucleic Acid-Based Neurological Disease Therapeutics in Each of the Seven Major World Healthcare Markets
  • Figure 4-12: Percentage Composition of The Market Potential For Nucleic Acid-Based Neurological Disease Therapeutics Among The Seven Major World Healthcare Markets Figure 4-13: Composition of the Market Potential for Nucleic Acid Therapeutics in the Global Healthcare Markets: 2004
  • Figure 4-14: Composition of the Market Potential for Nucleic Acid Therapeutics in the Seven Major World Healthcare Markets: 2004
  • Figure 4-15: Composition of the Market Potential for Nucleic Acid Therapeutics in the United States Healthcare Markets: 2004
  • Figure 4-16: Composition of the Market Potential for Nucleic Acid Therapeutics in the Japanese Healthcare Markets: 2004
  • Figure 4-17: Composition of the Market Potential for Nucleic Acid Therapeutics in the German Healthcare Markets: 2004
  • Figure 4-18: Composition of the Market Potential for Nucleic Acid Therapeutics in the French Healthcare Markets: 2004
  • Figure 4-19: Composition of the Market Potential for Nucleic Acid Therapeutics in the United Kingdoms Healthcare Markets: 2004
  • Figure 4-20: Composition of the Market Potential for Nucleic Acid Therapeutics in the Italian Healthcare Markets: 2004
  • Figure 4-21: Composition of the Market Potential for Nucleic Acid Therapeutics in the Spanish Healthcare Markets: 2004:

相關商品

細胞療法相關市場調查報告書

神經幹細胞·前驅細胞產品的策略性開發

Strategic Development of Neural Stem & Progenitor Cell Products

價格 : US $ 3495

出版日期 : 2012年01月

細胞治療:技術˙市場˙企業

Cell Therapy - Technologies, Markets and Companies

價格 : US $ 5500

出版日期 : 2012年01月

個別化醫療：科學的・商業的情勢

Personalized Medicine - scientific & commercial aspects

價格 : US $ 5000

出版日期 : 2012年01月

Kalorama Information發行的生物科技相關市場調查報告書

幹細胞：全球的幹細胞移植・臍帶血銀行・藥劑開發市場

Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

價格 : US $ 3995

出版日期 : 2012年01月

細胞培養:全球培養基·血清·試劑市場(第3版)

Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition

價格 : US $ 3500

出版日期 : 2011年10月

全球癌症治療和生物療法市場:第4版

The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition

價格 : US $ 3500

出版日期 : 2011年10月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!